Zevra Therapeutics (ZVRA) Gross Margin (2019 - 2026)
Zevra Therapeutics (ZVRA) posted Gross Margin of 94.76% for Q1 2026, down 0.83% on a QoQ basis from 95.55% in Q4 2025, and up 136.0% year-over-year from 40.15% in Q1 2025.
Zevra Therapeutics (ZVRA) Gross Margin (2019 - 2026) Analysis & Trends
Zevra Therapeutics' Gross Margin history runs 7 years deep, the most recent figure standing at 94.76% for Q1 2026.
- Quarterly Gross Margin rose 136.0% year-over-year to 94.76% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 86.08% (up 727.0% YoY) and the FY2025 annual result came in at 84.52%, up 1593.0% from the prior year.
- Gross Margin was 94.76% for Q1 2026 at Zevra Therapeutics, down from 95.55% in the prior quarter.
- Across five years, Gross Margin topped out at 98.4% in Q2 2022 and bottomed at 18.8% in Q2 2024.
- A 5-year average of 83.34% and a median of 94.82% in 2022 frame the typical range for Gross Margin.
- Annual changes were most pronounced in 2024 — Gross Margin plunged 7321 bps — and 2025, when it jumped 5758 bps.
- Zevra Therapeutics' Gross Margin stood at 95.45% in 2022, then fell by 5 bps to 90.5% in 2023, then dropped by 2 bps to 88.63% in 2024, then gained by 8 bps to 95.55% in 2025, then decreased by 1 bps to 94.76% in 2026.
- Business Quant data shows ZVRA's Gross Margin at 94.76% in Q1 2026, 95.55% in Q4 2025, and 95.25% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 88.95% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 86.85% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 91.79% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 90.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Zevra Therapeutics | 239.71 Mn | 39.10 Mn | 34.32 Mn | 94.76% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 94.76% |
| Dec 31, 2025 | 95.55% |
| Sep 30, 2025 | 95.25% |
| Jun 30, 2025 | 52.17% |
| Mar 31, 2025 | 93.41% |
| Dec 31, 2024 | 88.63% |
| Sep 30, 2024 | 37.67% |
| Jun 30, 2024 | 18.80% |
| Mar 31, 2024 | 94.89% |
| Dec 31, 2023 | 90.50% |
| Sep 30, 2023 | 95.03% |
| Jun 30, 2023 | 92.01% |
| Mar 31, 2023 | 96.06% |
| Dec 31, 2022 | 95.45% |
| Sep 30, 2022 | 94.87% |
| Jun 30, 2022 | 98.40% |
| Dec 31, 2021 | 97.71% |
| Sep 30, 2021 | 100.00% |
| Jun 30, 2021 | 91.66% |
| Sep 30, 2019 | 91.28% |